You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Estrogens, conjugated - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for estrogens, conjugated and what is the scope of freedom to operate?

Estrogens, conjugated is the generic ingredient in twelve branded drugs marketed by Wyeth Pharms, Teva Womens, Aspen, Wyeth Pharms Inc, Medpointe Pharm Hlc, and Wyeth Ayerst, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for estrogens, conjugated

US Patents:	0
Tradenames:	12
Applicants:	6
NDAs:	10
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	61
Patent Applications:	2,712
Formulation / Manufacturing:	see details
What excipients (inactive ingredients) are in estrogens, conjugated?	estrogens, conjugated excipients list
DailyMed Link:	estrogens, conjugated at DailyMed

Recent Clinical Trials for estrogens, conjugated

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
VA Office of Research and Development	Phase 2
Carol Fabian, MD	Early Phase 1
University of Kansas Medical Center	Phase 2

See all estrogens, conjugated clinical trials

Pharmacology for estrogens, conjugated

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for estrogens, conjugated

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-003	Jan 9, 1998		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Aspen	ENJUVIA	estrogens, conjugated synthetic b	TABLET;ORAL	021443-001	Dec 20, 2004		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Aspen	ENJUVIA	estrogens, conjugated synthetic b	TABLET;ORAL	021443-003	May 10, 2004		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for estrogens, conjugated

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PREMARIN	estrogens, conjugated	TABLET;ORAL	004782-003	Approved Prior to Jan 1, 1982	⤷ Try a Trial	⤷ Try a Trial
Wyeth Pharms	PREMARIN	estrogens, conjugated	TABLET;ORAL	004782-004	Approved Prior to Jan 1, 1982	⤷ Try a Trial	⤷ Try a Trial
Wyeth Pharms	PREMARIN	estrogens, conjugated	TABLET;ORAL	004782-005	Jan 26, 1984	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.